Company intelligence / Profile preview

Kurve Therapeutics

Ownership: Private
Development stage: Phase 2

Overview

Kurve Therapeutics has developed a patented intranasal drug delivery platform that bypasses the blood-brain barrier, delivering up to 30 times more medication directly to the brain than traditional infusions. The company has completed multiple Phase II studies and is preparing for Phase III trials across several indications. Their approach has been validated in at least 18 peer-reviewed clinical publications and ongoing collaborations with leading academic centers such as Harvard, Johns Hopkins, and Karolinska Institute

Therapeutic areas: NeurologyInfectious Diseases
Modalities: DeviceSmall molecule (as delivered via device)
Industry: Biotech

Drug pipeline

1 asset

intranasal insulin

Partnerships

Collaborations with major research institutions including Harvard University, Johns Hopkins University, and Karolinska Institute

Beyond the preview

Go deeper on Kurve Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kurve Therapeutics.

Explore the full profile